HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yuzuru Kanakura Selected Research

factor V Leiden

11/2002Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.
8/2002Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yuzuru Kanakura Research Topics

Disease

17Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria)
04/2022 - 04/2002
14Neoplasms (Cancer)
01/2021 - 05/2003
12Multiple Myeloma
01/2022 - 01/2011
11Hemolysis
04/2022 - 12/2006
9Anemia
11/2022 - 06/2007
8BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2020 - 03/2002
5Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
01/2020 - 08/2012
5Infections
01/2020 - 01/2003
5Thrombosis (Thrombus)
10/2013 - 05/2004
4Aplastic Anemia (Anemia, Hypoplastic)
01/2021 - 06/2007
4Graft vs Host Disease (Graft-Versus-Host Disease)
01/2021 - 11/2006
4Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2020 - 02/2003
4Essential Thrombocythemia
11/2018 - 01/2007
4Hematologic Neoplasms (Hematological Malignancy)
01/2016 - 01/2004
4Inflammation (Inflammations)
01/2011 - 10/2002
4Systemic Lupus Erythematosus (Libman-Sacks Disease)
05/2006 - 08/2002
3Myelodysplastic Syndromes (Myelodysplastic Syndrome)
11/2022 - 06/2007
3Bone Marrow Failure Disorders
08/2021 - 12/2018
3Thrombocytopenia (Thrombopenia)
01/2020 - 04/2005
3Headache (Headaches)
11/2018 - 10/2014
3Genetic Translocation (Chromosomal Translocation)
01/2012 - 03/2002
3Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
10/2009 - 08/2007
3Lymphoma (Lymphomas)
10/2009 - 01/2008
3Activated Protein C Resistance (APC Resistance)
03/2005 - 08/2002
2Autoimmune Hemolytic Anemia (Cold Agglutinin Disease)
09/2020 - 09/2012
2Encephalitis (Encephalitis, Rasmussen)
08/2020 - 05/2018
2Disease Progression
01/2020 - 01/2011
2Myeloid Leukemia (Leukemia, Myelocytic)
01/2020 - 01/2012
2Fibrosis (Cirrhosis)
01/2019 - 01/2009
2Acute Promyelocytic Leukemia
12/2018 - 05/2003
2Fever (Fevers)
05/2018 - 03/2010
2Hemorrhage
01/2017 - 12/2015
2Autoimmune Diseases (Autoimmune Disease)
12/2015 - 08/2003
2Thrombasthenia (Glanzmann Thrombasthenia)
07/2013 - 01/2011
2Pulmonary Hypertension
09/2012 - 08/2010
2Fatigue
01/2011 - 11/2002
2Dyspnea (Shortness of Breath)
01/2011 - 08/2010
2Plasmacytoma
01/2011 - 01/2011
2Leukemia
03/2009 - 05/2003
2Venous Thrombosis (Deep-Vein Thrombosis)
05/2006 - 11/2002
2Venous Thromboembolism
03/2005 - 08/2002
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
07/2021

Drug/Important Bio-Agent (IBA)

14eculizumabFDA Link
04/2022 - 01/2011
13Proteins (Proteins, Gene)FDA Link
08/2021 - 04/2002
7AntibodiesIBA
08/2020 - 08/2002
7Monoclonal AntibodiesIBA
02/2015 - 01/2008
6Lenalidomide (CC 5013)FDA Link
01/2022 - 01/2013
6Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA
08/2021 - 04/2002
5Dexamethasone (Maxidex)FDA LinkGeneric
01/2022 - 01/2013
5Complement System Proteins (Complement)IBA
09/2020 - 01/2011
5Phosphotransferases (Kinase)IBA
01/2020 - 03/2008
5Inosine Triphosphate (ITP)IBA
01/2020 - 08/2012
5Messenger RNA (mRNA)IBA
09/2015 - 08/2007
5Phospholipids (Phosphatides)FDA LinkGeneric
05/2006 - 08/2002
4Hemoglobins (Hemoglobin)IBA
04/2022 - 10/2005
4Melphalan (Alkeran)FDA LinkGeneric
02/2019 - 04/2014
4Bortezomib (Velcade)FDA Link
01/2016 - 01/2011
4Prothrombin (Factor II)IBA
05/2006 - 08/2002
3TESIBA
11/2020 - 07/2020
3ClathrinIBA
01/2020 - 01/2012
3IronIBA
01/2019 - 10/2002
3anagrelide (Agrylin)FDA LinkGeneric
11/2018 - 03/2013
3Prednisolone (Predate)FDA LinkGeneric
01/2017 - 04/2014
3AutoantibodiesIBA
12/2015 - 08/2003
3Immunoglobulin G (IgG)IBA
08/2012 - 08/2002
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2010 - 02/2003
3AdiponectinIBA
06/2007 - 01/2006
3PhosphatidylserinesIBA
05/2006 - 05/2004
3Cardiolipins (Cardiolipin)IBA
05/2006 - 05/2004
3beta 2-Glycoprotein I (Apolipoprotein H)IBA
03/2005 - 08/2002
3Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA
03/2005 - 08/2002
2Adenosine Triphosphate (ATP)IBA
01/2021 - 06/2014
2Complement Inactivating AgentsIBA
10/2020 - 01/2011
2Thrombopoietin ReceptorsIBA
01/2020 - 09/2013
2Thrombopoietin (c-mpl Ligand)IBA
01/2020 - 10/2008
2tyrosine receptor (receptor, tyrosine)IBA
01/2020 - 03/2008
2GPI-Linked ProteinsIBA
12/2019 - 03/2008
2CytokinesIBA
01/2019 - 04/2005
2AntigensIBA
01/2018 - 10/2013
2Adrenal Cortex Hormones (Corticosteroids)IBA
11/2016 - 09/2012
2L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
11/2016 - 01/2007
2SteroidsIBA
10/2016 - 09/2010
2Tyrosine (L-Tyrosine)FDA Link
06/2016 - 03/2009
2Pharmaceutical PreparationsIBA
01/2016 - 05/2013
2Rituximab (Mabthera)FDA Link
12/2015 - 10/2009
2Tyrosine Kinase InhibitorsIBA
09/2015 - 06/2014
2Imatinib Mesylate (Gleevec)FDA Link
06/2014 - 07/2010
2Transcription Factors (Transcription Factor)IBA
10/2013 - 12/2006
2DNA (Deoxyribonucleic Acid)IBA
01/2011 - 01/2003
2Anti-Idiotypic AntibodiesIBA
05/2006 - 05/2004
2factor V LeidenIBA
11/2002 - 08/2002
1Darbepoetin alfa (Aranesp)FDA Link
11/2022
1carfilzomibIBA
01/2022
1tesidolumabIBA
01/2022
1ixazomibIBA
04/2021

Therapy/Procedure

21Therapeutics
08/2021 - 01/2003
7Drug Therapy (Chemotherapy)
10/2019 - 01/2004
5Transplantation
07/2021 - 10/2016
4Hematopoietic Stem Cell Transplantation
01/2021 - 01/2016
4Bone Marrow Transplantation (Transplantation, Bone Marrow)
02/2019 - 11/2006